3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
50
Leukemia
15
Gastrointestinal Stromal Tumors
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia, Myeloid, Chronic-Phase
8
Neoplasms
5
Philadelphia Chromosome
4
Myeloproliferative Disorders
4
Leukemia, Myeloid
4
Bone Marrow Diseases
4
Blast Crisis
4
Hematologic Diseases
3
Hematologic Neoplasms
2
Bronchiolitis Obliterans Syndrome
2
Recurrence
1
Piebaldism
1
Neoplastic Processes
1
Neoplasms by Histologic Type
1
Melanoma
1
Mastocytosis, Systemic
1
Leukemia, Myeloid, Accelerated Phase
1
Hypereosinophilic Syndrome
1
Disease Progression
1
Interventions
tofacitinib
7
ibrutinib
6
ruxolitinib
3
ofatumumab
3
asciminib
3
Imatinib Mesylate
3
Dasatinib
3
nilotinib
2
bosutinib
2
Rituximab
2
Oxycodone
2
Naloxone
2
KW-2478
2
sodium luminolate
1
oblimersen
1
obinutuzumab
1
mocetinostat
1
milatuzumab
1
ixekizumab
1
fenebrutinib
1
canakinumab
1
belumosudil
1
baricitinib
1
axatilimab
1
abexinostat
1
Vision, Ocular
1
Sofosbuvir
1
Sirolimus
1
Saline Solution
1
Ribavirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Bronchiolitis Obliterans Syndrome
×
nilotinib
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA
NCT00802841
2015-11-16
LASOR
Novartis
Phase 3
Completed
191 enrolled
13 charts